Haemonetics Corporation Total Liabilities
Haemonetics Corporation total liabilities. Based on the latest financial reports, Haemonetics Corporation (HAE) has total liabilities worth $1.60 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See HAE days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Haemonetics Corporation (1992–2026)
Total liabilities of Haemonetics Corporation from 1992 to 2026. This chart illustrates how Haemonetics Corporation's total liabilities have evolved over time, based on quarterly financial data. Check Haemonetics Corporation liquidity resilience to evaluate the company's liquid asset resilience ratio.
Haemonetics Corporation Competitors by Total Liabilities
The table below lists competitors of Haemonetics Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ningbo Sanxing Medical Electric Co Ltd
SHG:601567
|
China | CN¥11.49 Billion |
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
USA | $287.74 Million |
|
Reysas Gayrimenkul Yatirim Ortakligi AS
IS:RYGYO
|
Turkey | TL10.90 Billion |
|
Guangdong Aofei Data Technology Co Ltd Class A
SHE:300738
|
China | CN¥12.63 Billion |
|
Shenzhen FRD Science & Technology Co Ltd
SHE:300602
|
China | CN¥4.68 Billion |
|
BRP Inc
TO:DOO
|
Canada | CA$5.71 Billion |
|
Henan Huanghe Whirlwind Co Ltd
SHG:600172
|
China | CN¥6.74 Billion |
|
Legend Holdings Corporation
F:1PC
|
Germany | €665.71 Billion |
Liability Composition Analysis (1992–2026)
This chart breaks down Haemonetics Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see HAE total assets.
Liquidity & Leverage Metrics
Haemonetics Corporation Total Liabilities Ratios Explained
Haemonetics Corporation total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Haemonetics Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Haemonetics Corporation (1992–2026)
The table below shows the annual total liabilities of Haemonetics Corporation from 1992 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | $1.50 Billion | -7.85% |
| 2025-03-31 | $1.63 Billion | +31.93% |
| 2024-03-31 | $1.24 Billion | +10.64% |
| 2023-03-31 | $1.12 Billion | +0.59% |
| 2022-03-31 | $1.11 Billion | +2.03% |
| 2021-03-31 | $1.09 Billion | +60.04% |
| 2020-03-31 | $680.00 Million | +12.05% |
| 2019-03-31 | $606.90 Million | +25.16% |
| 2018-03-31 | $484.91 Million | -2.84% |
| 2017-03-31 | $499.10 Million | -16.42% |
| 2016-03-31 | $597.13 Million | -9.11% |
| 2015-03-31 | $657.00 Million | -3.56% |
| 2014-03-31 | $681.23 Million | -1.65% |
| 2013-03-31 | $692.69 Million | +294.57% |
| 2012-03-31 | $175.56 Million | +19.32% |
| 2011-03-31 | $147.13 Million | -8.63% |
| 2010-03-31 | $161.02 Million | +46.64% |
| 2009-03-31 | $109.81 Million | -4.32% |
| 2008-03-31 | $114.76 Million | +23.28% |
| 2007-03-31 | $93.09 Million | -11.26% |
| 2006-03-31 | $104.89 Million | -6.86% |
| 2005-03-31 | $112.62 Million | -11.77% |
| 2004-03-31 | $127.64 Million | -6.12% |
| 2003-03-31 | $135.97 Million | +6.15% |
| 2002-03-31 | $128.10 Million | -1.31% |
| 2001-03-31 | $129.80 Million | -9.02% |
| 2000-03-31 | $142.67 Million | +6.07% |
| 1999-03-31 | $134.50 Million | -5.28% |
| 1998-03-31 | $142.00 Million | +44.60% |
| 1997-03-31 | $98.20 Million | +38.70% |
| 1996-03-31 | $70.80 Million | -18.90% |
| 1995-03-31 | $87.30 Million | +24.89% |
| 1994-03-31 | $69.90 Million | +30.41% |
| 1993-03-31 | $53.60 Million | -1.11% |
| 1992-03-31 | $54.20 Million | -- |
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information tech… Read more